Abstract:Background & aims: Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line therapy for patients with metastatic colorectal tumors without RAS mutations. However, EGFR inhibitors are ineffective in these patients, and tumor level of EGFR does not associate with response to therapy. We screened human colorectal tumors for EGFR-positive myeloid cells and investigated their association with patient outcome. We also performed studies in mice to evaluate how EGFR expression in tumor cells and myeloid cells contributes to development of colitis-associated cancer and ApcMin-dependent intestinal tumorigenesis. Methods: We performed immunohistochemical and immunofluorescent analyses of 116 colorectal tumor biopsies to determine levels of EGFR in tumor and stroma; we also collected information on tumor stage and patient features and outcomes. We used the Mann-Whitney U and Kruskal-Wallis tests to correlate tumor levels of EGFR with tumor stage, and the Kaplan-Meier method to estimate patients' median survival time. We performed experiments in mice lacking EGFR in intestinal epithelial cells (Villin-Cre; Egfrf/f and Villin-CreERT2; Egfrf/f mice) or myeloid cells (LysM-Cre; Egfrf/f mice) on a mixed background. These mice were bred with ApcMin/+ mice; colitis-associated cancer and colitis were induced by administration of dextran sodium sulfate (DSS), with or without azoxymethane (AOM), respectively. Villin-CreERT2 was activated in developed tumors by administration of tamoxifen to mice. Littermates that expressed full-length EGFR were used as controls. Intestinal tissues were collected; severity of colitis, numbers and size of tumors, and intestinal barrier integrity were assessed by histologic, immunohistochemical, quantitative reverse transcription polymerase chain reaction, and flow cytometry analyses. Results: We detected EGFR in myeloid cells in the stroma of human colorectal tumors; myeloid cell expression of EGFR associated with tumor metastasis and shorter patient survival time. Mice with deletion of EGFR from myeloid cells formed significantly fewer and smaller tumors than the respective EGFR-expressing controls in an ApcMin/+ background as well as after administration of AOM and DSS. Deletion of EGFR from intestinal epithelial cells did not affect tumor growth. Furthermore, tamoxifen-induced deletion of EGFR from epithelial cells of established intestinal tumors in mice given AOM and DSS did not reduce tumor size. EGFR signaling in myeloid cells promoted activation of STAT3 and expression of survivin in intestinal tumor cells. Mice with deletion of EGFR from myeloid cells developed more severe colitis after DSS administration, characterized by increased intestinal inflammation and intestinal barrier disruption, than control mice or mice with deletion of EGFR from intestinal epithelial cells. EGFR-deficient myeloid cells in the colon of DSS-treated LysM-Cre; Egfrf/f mice had reduced expression of interleukin 6 (IL6), and epithelial STAT3 activation was reduced compared with controls. Administration of recombinant IL6 to LysM-Cre; Egfrf/f mice given DSS protected them from weight loss and restored epithelial proliferation and STAT3 activation, compared with administration of DSS alone to these mice. Conclusions: Increased expression of EGFR in myeloid cells from the colorectal tumor stroma associates with tumor progression and reduced survival time of patients with metastatic colorectal cancer. Deletion of EGFR from myeloid cells, but not intestinal epithelial cells, protects mice from colitis-induced intestinal cancer and ApcMin-dependent intestinal tumorigenesis. Myeloid cell expression of EGFR increases activation of STAT3 and expression of survivin in intestinal epithelial cells and expression of IL6 in colon tissues. These findings indicate that expression of EGFR by myeloid cells of the colorectal tumor stroma, rather than the cancer cells themselves, contributes to tumor development.

190 Oncogenic K-RAS Regulates Expression of CCK2 Receptor Splice Variant in Human Colon Cancer Cells

Identification of Novel Nrf2 Target Genes As Prognostic Biomarkers in Colitis-Associated Colorectal Cancer in Nrf2-deficient Mice

Data from Genome-Wide Association and Fine Mapping of Genetic Loci Predisposing to Colon Carcinogenesis in Mice

Abstract 2187: Influences of high-fat diet on tumor biology in a mouse model of colorectal cancer

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients

Enhanced Expression of Cholecystokinin-2 Receptor Promotes the Progression of Colon Cancer Through Activation of Focal Adhesion Kinase.

Identification of Mutation Biomarkers Underpinning Colon Cancer Sidedness and Cetuximab Sensitivity.

Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer

Elevated Protein Expression of Cyclin D1 and Fra‐1 but Decreased Expression of C‐myc in Human Colorectal Adenocarcinomas Overexpressing Β‐catenin

Monocarboxylate Transporter-2 Expression Restricts Tumor Growth in a Murine Model of Lung Cancer: A Multi-Omic Analysis

Expression of the Novel Adipokine C1qTNF-related Protein 4 (CTRP4) Suppresses Colitis and Colitis-Associated Colorectal Cancer in Mice

Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway.

Connective Tissue Growth Factor Is Overexpressed in Esophageal Squamous Cell Carcinoma and Promotes Tumorigenicity through β-Catenin-T-cell Factor/Lef Signaling

WNT Oncogenic Transcription Requires MYC Suppression of Lysosomal Activity and EPCAM Stabilization in Gastric Tumors

High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.

C-Kit Signaling Promotes Proliferation and Invasion of Colorectal Mucinous Adenocarcinoma in A Murine Model

917 Activation of T Lymphocytes and Macrophage Contributes to IL-1β-Induced Gastric Inflammation and Carcinogenesis

Single-cell analysis unveils activation of mast cells in colorectal cancer microenvironment

Rapid Tyrosine Phosphorylation of Focal Adhesion Kinase, Paxillin, and P130cas by Gastrin in Human Colon Cancer Cells.

Loss of tumor necrosis factor‐alpha diminishes indicators of colonic Wnt‐signaling activation induced by obesity

BMI1 and MEL18 Promote Colitis-Associated Cancer in Mice Via REG3B and STAT3